{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:45:05Z","timestamp":1793663105536,"version":"4.5.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023864","name":"NHS Innovation Accelerator","doi-asserted-by":"publisher","award":["R00AG065457"],"award-info":[{"award-number":["R00AG065457"]}],"id":[{"id":"10.13039\/501100023864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ajgponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jagp.2024.05.007","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T09:13:26Z","timestamp":1716110006000},"page":"1047-1059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of Psychedelics in Older Adults: A Prospective Cohort Study"],"prefix":"10.1016","volume":"32","author":[{"given":"Hannes","family":"Kettner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leor","family":"Roseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gazzaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0001","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1037\/0003-066X.54.3.165","article-title":"Taking time seriously: a theory of socioemotional selectivity","volume":"54","author":"Carstensen","year":"1999","journal-title":"Am Psychol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1024569803230","article-title":"Socioemotional selectivity theory and the regulation of emotion in the second half of life","volume":"27","author":"Carstensen","year":"2003","journal-title":"Motivat Emot"},{"issue":"7","key":"10.1016\/j.jagp.2024.05.007_bib0003","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jagp.2013.01.006","article-title":"The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease","volume":"21","author":"Rosenberg","year":"2013","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9","key":"10.1016\/j.jagp.2024.05.007_bib0004","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.biopsych.2012.02.002","article-title":"Depressive symptoms and mild cognitive impairment in the elderly: an ominous combination","volume":"71","author":"Steffens","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.jagp.2024.05.007_bib0005","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/gps.4495","article-title":"Loneliness, depression and cognitive function in older U.S. adults","volume":"32","author":"Donovan","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"10.1016\/j.jagp.2024.05.007_bib0006","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jagp.2020.08.005","article-title":"Social isolation and loneliness in older adults: review and commentary of a national academies report","volume":"28","author":"Donovan","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.jagp.2024.05.007_bib0007","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jagp.2023.01.008","article-title":"Can emotional well-being maintain health and prevent suicide in later life? A national priority for research","volume":"31","author":"Conwell","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.jagp.2024.05.007_bib0008","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.socscimed.2011.11.028","article-title":"Loneliness, health, and mortality in old age: a national longitudinal study","volume":"74","author":"Luo","year":"2012","journal-title":"Soc Sci Med"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0009","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12160-010-9210-8","article-title":"Loneliness matters: a theoretical and empirical review of consequences and mechanisms","volume":"40","author":"Hawkley","year":"2010","journal-title":"Annals Behav Med"},{"issue":"9789","key":"10.1016\/j.jagp.2024.05.007_bib0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","article-title":"Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial","volume":"378","author":"Banerjee","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0011","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","article-title":"Sertraline for the treatment of depression in Alzheimer disease","volume":"18","author":"Rosenberg","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"issue":"15","key":"10.1016\/j.jagp.2024.05.007_bib0012","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0013","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatrica Scandin"},{"issue":"17","key":"10.1016\/j.jagp.2024.05.007_bib0014","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/a-1721-2914","article-title":"Classic psychedelic drugs: update on biological mechanisms","volume":"55","author":"Vollenweider","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0016","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0017","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.jagp.2024.05.007_bib0018","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/j.jagp.2024.05.007_bib0019","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00213-020-05703-9","article-title":"Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs","volume":"237","author":"Kangaslampi","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/02698811231215420","article-title":"Older adults in psychedelic-assisted therapy trials: a systematic review","volume":"38","author":"Bouchet","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jagp.2022.08.007","article-title":"The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns","volume":"31","author":"Johnston","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0022","series-title":"How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence","author":"Pollan","year":"2019"},{"key":"10.1016\/j.jagp.2024.05.007_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fnsyn.2020.00034","article-title":"Psychedelics as a treatment for Alzheimer's disease dementia","volume":"12","author":"Vann Jones","year":"2020","journal-title":"Front Synaptic Neurosci"},{"issue":"4","key":"10.1016\/j.jagp.2024.05.007_bib0024","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jagp.2022.01.261","article-title":"Cannabinoids and psychedelics for neuropsychiatric symptoms of Alzheimer's: addressing disparities through clinical trials","volume":"30","author":"Forester","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2023.07.003","article-title":"The potential of psychedelics for the treatment of Alzheimer's disease and related dementias","volume":"76","author":"Winkelman","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0026","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jagp.2022.12.201","article-title":"Psychedelics for the neuropsychiatric symptoms of Alzheimer's disease","volume":"31","author":"Sarangi","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0027","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13670-023-00395-3","article-title":"The potential for psychedelics to improve coping skills and resilience in persons with newly diagnosed mild cognitive impairment or early Alzheimer's disease","volume":"12","author":"Steinberg","year":"2023","journal-title":"Curr Geriatr Rep"},{"key":"10.1016\/j.jagp.2024.05.007_bib0028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s41465-019-00151-6","article-title":"Can psychedelic drugs attenuate age-related changes in cognition and affect?","volume":"4","author":"Aday","year":"2020","journal-title":"J Cognit Enhanc"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jagp.2022.09.017","article-title":"Expending perspectives on the potential for psychedelic-assisted therapies to improve the experience of aging","volume":"31","author":"Beaussant","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.735427","article-title":"Self-medication for chronic pain using classic psychedelics: a qualitative investigation to inform future research","volume":"12","author":"Bornemann","year":"2021","journal-title":"Front Psychiatry"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0031","first-page":"45","article-title":"Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics","volume":"2","author":"Mason","year":"2018","journal-title":"J Psych Studies"},{"key":"10.1016\/j.jagp.2024.05.007_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.780696","article-title":"Psychedelic mushrooms in the USA: knowledge, patterns of use, and association with health outcomes","volume":"12","author":"Matzopoulos","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.659044","article-title":"Psilocybin: from serendipity to credibility?","volume":"12","author":"Rucker","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0034","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fphar.2021.623985","article-title":"Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness","volume":"12","author":"Kettner","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0035","series-title":"An Amazonian shamanic brew in Australia: Ayahuasca healing and individualism","author":"Gearin","year":"2015"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0036","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13537900050005976","article-title":"Field tripping: psychedelic communitas and ritual in the Australian bush","volume":"15","author":"Tramacchi","year":"2000","journal-title":"J Contemp Religion"},{"key":"10.1016\/j.jagp.2024.05.007_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/00221678211043300","article-title":"\u201cMeeting the medicine halfway\u201d: Ayahuasca ceremony leaders\u2019 perspectives on preparation and integration practices for participants","author":"Callon","year":"2021","journal-title":"J Human Psychol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0038","article-title":"Psychological effects of psychedelics in adolescents","volume":"3","author":"Izmi","year":"2024","journal-title":"Front Child Adol Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0039","article-title":"Predictors of hallucinogen persisting perception disorder symptoms, delusional ideation and magical thinking following naturalistic psychedelic use","author":"Zhou","year":"2022","journal-title":"PsyArXiv"},{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"issue":"11","key":"10.1016\/j.jagp.2024.05.007_bib0041","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/sim.4200","article-title":"Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples","volume":"30","author":"Austin","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-5-63","article-title":"The Warwick-Edinburgh mental well-being scale (WEMWBS): development and UK validation","volume":"5","author":"Tennant","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jagp.2024.05.007_bib0043","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)","volume":"10","author":"Nour","year":"2016","journal-title":"Front Human Neurosci"},{"issue":"11","key":"10.1016\/j.jagp.2024.05.007_bib0044","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/j.jagp.2024.05.007_bib0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0046","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s11135-017-0584-6","article-title":"Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour","volume":"52","author":"Johnston","year":"2018","journal-title":"Qual Quant"},{"key":"10.1016\/j.jagp.2024.05.007_bib0047","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fpsyt.2021.687615","article-title":"Ceremonial Ayahuasca in Amazonian retreats\u2014mental health and epigenetic outcomes from a six-month naturalistic study","volume":"12","author":"Ruffell","year":"2021","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0048","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/02791072.2019.1580804","article-title":"Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being","volume":"51","author":"Mason","year":"2019","journal-title":"J Psycho Drugs"},{"key":"10.1016\/j.jagp.2024.05.007_bib0049","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00213-021-05817-8","article-title":"A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats","volume":"238","author":"Uthaug","year":"2021","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.jagp.2024.05.007_bib0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0051","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3389\/fpsyg.2022.866018","article-title":"Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a transdiagnostic, trans-drug model","volume":"13","author":"Brennan","year":"2022","journal-title":"Front Psychol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.800072","article-title":"Psychedelic therapy's transdiagnostic effects: a research domain criteria (RDoC) perspective","volume":"12","author":"Kelly","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jagp.2024.05.007_bib0053","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fpsyt.2021.661233","article-title":"Does psychedelic therapy have a transdiagnostic action and prophylactic potential?","volume":"12","author":"Ko\u010d\u00e1rov\u00e1","year":"2021","journal-title":"Front Psychiatry"},{"issue":"8","key":"10.1016\/j.jagp.2024.05.007_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291723003653","article-title":"Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression","volume":"54","author":"Szigeti","year":"2024","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/NAN.S27184","article-title":"Differences in risk aversion between young and older adults","volume":"2012","author":"Albert","year":"2012","journal-title":"Neurosci Neuroecon"},{"issue":"9968","key":"10.1016\/j.jagp.2024.05.007_bib0056","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(13)61489-0","article-title":"Subjective wellbeing, health, and ageing","volume":"385","author":"Steptoe","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jagp.2024.05.007_bib0057","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.socscimed.2008.01.030","article-title":"Is well-being U-shaped over the life cycle?","volume":"66","author":"Blanchflower","year":"2008","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jagp.2024.05.007_bib0058","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: a systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jagp.2024.05.007_bib0059","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3389\/fpsyt.2021.647909","article-title":"Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample","volume":"12","author":"Mans","year":"2021","journal-title":"Front Psychiatry"},{"issue":"24","key":"10.1016\/j.jagp.2024.05.007_bib0060","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.3390\/ijerph16245147","article-title":"From egoism to ecoism: psychedelics increase nature relatedness in a state-mediated and context-dependent manner","volume":"16","author":"Kettner","year":"2019","journal-title":"Int J Environ Res Public health"},{"issue":"5","key":"10.1016\/j.jagp.2024.05.007_bib0061","doi-asserted-by":"crossref","DOI":"10.1177\/1363461520983684","article-title":"Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy","volume":"59","author":"Gukasyan","year":"2021","journal-title":"Transcult Psychiatry"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0062","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0063","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0064","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jagp.2024.05.007_bib0066","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front Psychiatry"},{"issue":"3","key":"10.1016\/j.jagp.2024.05.007_bib0068","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0069","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2147\/NDT.S426193","article-title":"Predicting the intensity of psychedelic-induced mystical and challenging experience in a healthy population: an exploratory post-hoc analysis","volume":"19","author":"Ko","year":"2023","journal-title":"Neuropsychiatr Dis Treatment"},{"issue":"8","key":"10.1016\/j.jagp.2024.05.007_bib0070","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/02698811221084063","article-title":"Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms","volume":"36","author":"Kopra","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jagp.2024.05.007_bib0071","doi-asserted-by":"crossref","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jagp.2024.05.007_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1232459","article-title":"The ego in psychedelic drug action\u2014ego defenses, ego boundaries, and the therapeutic role of regression","volume":"17","author":"Buchborn","year":"2023","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0073","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1556\/2054.2023.00243","article-title":"Association between mystical-type experiences under psychedelics and improvements in well-being or mental health\u2014a comprehensive review of the evidence","volume":"7","author":"Kangaslampi","year":"2023","journal-title":"J Psyched Studies"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0074","doi-asserted-by":"crossref","DOI":"10.1177\/02698811211066709","article-title":"Validation of the Psychological Insight Scale: a new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.jagp.2024.05.007_bib0075","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1037\/dev0000349","article-title":"Getting together: social contact frequency across the life span","volume":"53","author":"Sander","year":"2017","journal-title":"Develop Psychol"},{"key":"10.1016\/j.jagp.2024.05.007_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101400","article-title":"A systematic review of the impacts of intergenerational engagement on older adults\u2019 cognitive, social, and health outcomes","volume":"71","author":"Krzeczkowska","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.jagp.2024.05.007_bib0077","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/13607863.2014.933309","article-title":"The effect of intergenerational programs on the mental health of elderly adults","volume":"19","author":"Murayama","year":"2015","journal-title":"Aging Mental health"},{"key":"10.1016\/j.jagp.2024.05.007_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2019.03.021","article-title":"Reduced serotonin receptors and transporters in normal aging adults: a meta-analysis of PET and SPECT imaging studies","volume":"80","author":"Karrer","year":"2019","journal-title":"Neurobiol Aging"},{"issue":"7","key":"10.1016\/j.jagp.2024.05.007_bib0079","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jagp.2024.05.007_bib0080","first-page":"1","article-title":"Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey","volume":"239","author":"Kuc","year":"2021","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jagp.2024.05.007_bib0081","doi-asserted-by":"crossref","first-page":"13645","DOI":"10.1038\/s41598-023-40856-5","article-title":"Co-use of MDMA with psilocybin\/LSD may buffer against challenging experiences and enhance positive experiences","volume":"13","author":"Zeifman","year":"2023","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1016\/j.jagp.2024.05.007_bib0082","doi-asserted-by":"crossref","first-page":"e25973","DOI":"10.2196\/25973","article-title":"Turn on, tune in, and drop out: predictors of attrition in a prospective observational cohort study on psychedelic use","volume":"23","author":"H\u00fcbner","year":"2021","journal-title":"J Med Internet Res"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748124003361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748124003361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:26:52Z","timestamp":1723087612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748124003361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1064748124003361"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2024.05.007","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Psychedelics in Older Adults: A Prospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2024.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Association for Geriatric Psychiatry.","name":"copyright","label":"Copyright"}]}}